Clinical trials: Mild and Moderate Alzheimer's Disease
Alzheimer Disease
Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease
The study is to evaluate the safety, tolerability and whether there is an immune system response to multiple doses of ACC-001 with or without the use of a substance that may increase the response to the drug.
- Trial name
- NCT00752232
- Testing
- ACC-001, QS-21, PBS
- Where
- 10 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Pfizer
Alzheimer's Disease
A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease
The purpose of this study is to examine the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single dose of PF-04360365 in Japanese subjects with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00607308
- Testing
- PF-04360365
- Where
- 9 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Pfizer
Alzheimer's Disease, Sleep Disorder
Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
The aim of this exploratory randomized, placebo controlled study is to evaluate the efficacy of Circadin® 2mg in patients with mild to moderate Alzheimer Disease (AD) treated with the acetylcholinesterase (AChE) inhibitor.
- Trial name
- NCT00940589
- Testing
- Circadin
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 73 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Alzheimer's Disease
Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease
The primary purpose of this study is to assess the safety and tolerability of TRx0237 when taken at the same time as acetylcholinesterase inhibitors (i.e., donepezil, galantamine, or rivastigmine) and / or memantine to treat…
- Trial name
- NCT01626391
- Testing
- TRx0237
- Where
- 12 sites in Germany, United Kingdom
- Volunteers
- 9 people
- Sponsor
- TauRx Therapeutics Ltd
Alzheimer's Disease
Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid
The purpose of this study was to evaluate the efficacy and safety of plasma exchange with 5% albumin in beta-amyloid peptide clearance in cerebrospinal fluid, and its effects in patients with mild-moderate Alzheimer's disease.
- Trial name
- NCT00742417
- Testing
- Albutein 5%, Control
- Where
- 4 sites in United States, Spain
- Volunteers
- 42 people
- Sponsor
- Instituto Grifols, S.A.
Alzheimer's Disease
A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease
This is a Phase I, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7105705 in two participant populations: healthy participants and…
- Trial name
- NCT02820896
- Testing
- RO7105705
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Alzheimer Disease
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.
- Trial name
- RESOLVE (NCT07633470)
- Testing
- Zunveyl®
- Where
- 22 sites in United States
- Volunteers
- 150 people
- Sponsor
- Alpha Cognition, Inc
Alzheimer's Disease
SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)
The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00093951
- Testing
- SGS742
- Where
- 59 sites in United States
- Volunteers
- 280 people
- Sponsor
- Saegis Pharmaceuticals
Alzheimer's Disease
Anti-Oxidant Treatment of Alzheimer's Disease
The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00117403
- Testing
- Vitamin E, Vitamin C, and Alpha-lipoic Acid, Coenzyme Q
- Where
- 13 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institute on Aging (NIA)
Alzheimer's Disease
Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease
A double blind, placebo-controlled randomized study to evaluate the efficacy and safety of orally administered Tamibarotene to patients of Alzheimer's Disease
- Trial name
- NCT01120002
- Testing
- Tamibarotene
- Where
- Japan
- Volunteers
- 50 people
- Sponsor
- Osaka City University
Parkinson Disease
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease
The purpose of this study is to determine the safety, tolerability and blood levels of orally administered anle138b as well as the effect of food and early signs of efficacy in patients with mild to moderate Parkinson´s disease.
- Trial name
- NCT04685265
- Testing
- anle138b
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- MODAG GmbH
Alzheimer's Disease
Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study was to investigate the 5cm^2 and 10cm^2 doses of rivastigmine transdermal patch in terms of efficacy and safety in patients with probable Alzheimer's Disease (MMSE [Mini Mental State Examination] 10-20).
- Trial name
- NCT00423085
- Testing
- Rivastigmine transdermal patch
- Where
- Japan
- Volunteers
- 859 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease, Dementia
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity.
- Trial name
- NCT06721156
- Testing
- MK-1167
- Where
- 72 sites in United States, Argentina and 7 more
- Volunteers
- 369 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease
Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease
The purpose of the study is to examine the safety and tolerability of a multiple dose of PF-04360365 administered over approximately 10 minutes in Japanese patients with mild-to-moderate Alzheimer's disease and to characterize…
- Trial name
- NCT01125631
- Testing
- PF-04360365 8.5 mg/kg
- Where
- 4 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Pfizer
Alzheimer´s Disease
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease
The purpose of this study was to evaluate the efficacy and safety of 2 doses of Immune Globulin Intravenous (IGIV), 10% administered every 2 weeks as an intravenous (IV) infusion compared with placebo in participants with mild to…
- Trial name
- NCT00818662
- Testing
- Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg, Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg
- Where
- 41 sites in United States, Canada
- Volunteers
- 390 people
- Sponsor
- Baxalta now part of Shire
Alzheimer's Disease
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine in a 12-week treatment study if MEM 1003 is a safe and effective treatment for patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00257673
- Testing
- MEM 1003
- Where
- 57 sites in United States
- Volunteers
- 183 people
- Sponsor
- Memory Pharmaceuticals
Alzheimer's Disease
A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension
This is Phase 3 study, multi-centre, double-blind, placebo controlled, parallel group to evaluate the effects of AC-SD-03 on the efficacy and safety among participants with mild to moderate Alzheimer's Disease.
- Trial name
- NCT04187547
- Testing
- Tricaprilin
- Sponsor
- Cerecin
Alzheimer's Disease
Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease
This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with mild to moderate Alzheimer's disease
- Trial name
- NCT01009255
- Testing
- GSK239512
- Where
- 35 sites in Bulgaria, Chile and 6 more
- Volunteers
- 196 people
- Sponsor
- GlaxoSmithKline